New, Expanded Offerings From McKesson Specialty Health Help Community Oncology Practices Overcome Challenges to Better Care for

McKesson Specialty Health unveils its newly expanded and enhanced Onmark Select Program providing oncologists with flexibility, choice and value

THE WOODLANDS, Texas, Sept. 19, 2011 /PRNewswire/ -- In today's dynamic healthcare environment, community-based oncologists face increasing challenges. To empower community-based oncology practices to remain independent, grow and deliver high-quality care to patients in the midst of these challenges, McKesson Specialty Health unveiled today its Onmark Select Program.

(Logo: http://photos.prnewswire.com/prnh/20110912/DA65711LOGO)

"Community-based cancer care is a precious resource.  Between reimbursement pressures, rising costs, increasing competition and the uncertainty of healthcare reform, community oncology practices face a challenging environment," said Bruce Broussard, CEO, McKesson Specialty Health. "McKesson Specialty Health's Onmark Select Program provides flexible solutions to help practices perform under pressure, allowing each practice to engage with our broad array of proven clinical, technology and business support services in its own way.  Onmark Select helps practices meet today's challenges head on, allowing them to remain independent, grow, and advance patient care."

The Onmark Select Program, delivered through McKesson Specialty Health's Solutions for Oncology, empowers vibrant and sustainable independent community-based oncology practices to advance the science, technology and quality of care through proven, customizable services. Engaging with McKesson Specialty Health through the Onmark Select Program allows practices to thrive in today's challenging environment, achieve their business and clinical goals, and ultimately better the health of the practices and the patients they serve. Practices participating in the Onmark Select Program benefit from McKesson Specialty Health's expertise and leadership in advanced technology, business and operational support and clinical support.

Advanced Technology

McKesson Specialty Health's deep understanding of oncology practices fuels the development of its technology.  The result is an integrated technology platform to enhance practice operations, workflow and clinical decision-making through leading technology solutions including:

  • iKnowMed Electronic Health Record
  • Lynx Mobile drug inventory management system
  • Lynx TotalView claims and remittance analytics tool
  • ePrescribing support system
  • Regimen Profiler financial analysis tool
  • Clinical Trials Management System

Business and Operational Leadership

McKesson Specialty Health works strategically to help community practices grow and operate more efficiently through streamlined operations, group purchasing, and payer contracting support including.

  • Payer contracting and reimbursement
    • Practice resources and assessment
    • Practice management consulting:
      • Revenue cycle
      • Managed care
      • Clinical care
  • Drug management, purchasing and distribution services
  • Supply chain management
  • Practice growth services
  • Practice management resources and updates

Clinical Leadership

McKesson Specialty Health provides oncologists with resources to help drive evidence-based medicine, increase clinical trials access and provide enhanced patient educational materials including:

  • Clinical collaboration
  • Treatment guidelines and pathways
  • Patient educational materials
  • Medication therapy management forms
  • Patient financial support tools
  • Access to one of the nation's largest networks of community-based oncology researchers

Flexible Solutions to Strengthen Community Practices

The Onmark Select Program offers a highly flexible way for practices to benefit from the expertise of McKesson Specialty Health through a relationship that allows the practice to take advantage of specific services of their choosing. Participation in Onmark Select can range from a drug distribution or technology relationship to the fully-engaged relationship with access to an integrated technology platform built for oncology, clinical support, practice marketing support, a generics loyalty program, payer contracting and reimbursement support to improve a practice's managed care position, and participation in a world-class clinical research program.

"Through a flexible range of services, the Onmark Select Program helps practices gain purchasing efficiencies, grow patient volumes, optimize revenue and enhance productivity so community oncologists can focus on what they do best: provide advanced, high-quality care to patients fighting cancer," said Mark Walchirk, President, McKesson Specialty Health. "Our innovative clinical and business capabilities and our advanced, integrated technology strengthen community-based practices.  Through our unmatched breadth and depth of services and expertise, we offer community oncology practices a competitive advantage in challenging times."

For more details on The Onmark Select Program and its offerings, visit www.mckessonspecialtyhealth.com/oncology.

About McKesson Specialty Health

McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our customers and help them provide quality care for patients. For more information, visit www.mckessonspecialtyhealth.com.

About McKesson

McKesson Corporation, currently ranked 15th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit www.mckesson.com.

SOURCE McKesson Specialty Health

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.